EMEA-002358-PIP02-18

Key facts

Active substance
avapritinib
Therapeutic area
Oncology
Decision number
P/0026/2019
PIP number
EMEA-002358-PIP02-18
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Oral use
Contact for public enquiries
Blueprint Medicines (Netherlands) B.V.

E-mail: medinfo@blueprintmedicines.com
Tel. +1 6177 146707

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating